Status:
COMPLETED
18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)
Lead Sponsor:
University Health Network, Toronto
Conditions:
Stage III Ovarian Cancer
Stage IV Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether high grade epithelial ovarian cancers (=HG EOC) are 18F-DCFPyL (=2-(3-(1-carboxy-5-\[(6-\[18F\]fluoro-pyridine-3-carbonyl)-amino\]-pentyl)-ureido)-pen...
Detailed Description
In patients with ovarian cancer, identifying the volume and exact locations of disease is of paramount importance prior to deciding on upfront surgery versus chemotherapy. Currently, most clinicians u...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Cytological or histological diagnosis of high grade epithelial ovarian cancer, or clinical suspicious of HG EOC based on symptoms, physical exam, tumor markers and imaging findings.
- Clinical stage III or IV, being considered for primary debulking surgery or NACT.
- Contrast-enhanced CT abdomen and pelvis within 6 weeks of PET (prior to enrollment).
Exclusion
- Inability to provide informed consent.
- Contraindication for PET examination as per institutional safety guidelines, including but not limited to pregnancy, or inability to lie still for PET examination.
- Evidence of the following epithelial ovarian cancer histological subtypes: Mucinous, low grade serous, low grade endometrioid and low-malignant potential tumors.
Key Trial Info
Start Date :
April 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 13 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03811899
Start Date
April 1 2019
End Date
October 13 2022
Last Update
November 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9